Revvity (BMV:RVTY *) - Hisse Senedi Fiyatı, Haberler ve Analizler

RVTY * Stoklara Genel Bakış

Provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. Daha fazla detay

RVTY * temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	2/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Kazançların yılda 14.99% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Kar marjları (11.7%) geçen yılın (20%) altında

Revvity, Inc. Rakipler

Sartorius Stedim Biotech

ENXTPA:DIM

€17.4b

Divi's Laboratories

NSEI:DIVISLAB

₹1.6t

Sartorius

XTRA:SRT3

€13.6b

Waters

NYSE:WAT

US$22.2b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Revvity
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2,420.00
52 Haftanın En Yüksek Seviyesi	US$2,595.00
52 Haftanın En Düşük Seviyesi	US$2,343.00
Beta	1.09
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-18.16%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	35.26%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	RVTY *	MX Life Sciences	MX Pazar
7D	0%	0%	0%
1Y	-18.2%	0%	0%

Getiri vs. Endüstri: RVTY * geçen yıl % 1.7 oranında getiri sağlayan MX Life Sciences sektörünün gerisinde kaldı.

Getiri vs Piyasa: RVTY * geçen yıl % -3.3 oranında getiri sağlayan MX Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is RVTY *'s price volatile compared to industry and market?
RVTY * volatility
RVTY * Average Weekly Movement	n/a
Life Sciences Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

İstikrarlı Hisse Senedi Fiyatı: RVTY * son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: RVTY * 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1937	16,700	Prahlad Singh	www.revvity.com

Revvity, Inc. Temel Bilgiler Özeti

Revvity'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RVTY * temel i̇stati̇sti̇kler
Piyasa değeri	Mex$278.82b
Kazançlar(TTM)	Mex$6.00b
Gelir(TTM)	Mex$51.35b

46.4x

F/K Oranı

5.4x

P/S Oranı

RVTY * aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RVTY * gelir tablosu (TTM)
Gelir	US$3.02b
Gelir Maliyeti	US$1.21b
Brüt Kâr	US$1.81b
Diğer Giderler	US$1.46b
Kazançlar	US$353.45m

Son Raporlanan Kazançlar

Apr 02, 2023

Sonraki Kazanç Tarihi

Aug 01, 2023

Hisse başına kazanç (EPS)	2.82
Brüt Marj	59.86%
Net Kâr Marjı	11.69%
Borç/Özkaynak Oranı	54.3%

RVTY * uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.2%

Mevcut Temettü Verimi

10%

Ödeme Oranı

RVTY * Stoklara Genel Bakış

Ödüller

Risk Analizi

Revvity, Inc. Rakipler

ENXTPA:DIM

€17.4b

NSEI:DIVISLAB

₹1.6t

XTRA:SRT3

€13.6b

NYSE:WAT

US$22.2b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells

Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares.

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025

Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Recent updates

Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells

Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares.

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025

Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024

Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

Insufficient new directors

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021)

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021)

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021)

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021)

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors

PerkinElmer, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc.(NYSE:PKI) dropped from Russell 1000 Value-Defensive Index